Tirzepatide and pregnancy planning need less lead time than Wegovy

The Wegovy label tells patients to stop semaglutide at least 2 months before a planned pregnancy. The Zepbound label sets no fixed washout at all. It says to stop once a pregnancy is recognized, and the practical gap comes down to half-life. If you're weighing tirzepatide and pregnancy timing, that difference matters more than any headline about the drug class.

Both labels agree on the bigger picture. Weight loss offers no benefit during pregnancy, animal studies flagged fetal risks, and the human data on GLP-1 and pregnancy are still too thin to rule a risk in or out. What follows is what the FDA labels and published studies actually say, so you can bring sharper questions to your prescriber. Redose logs doses and dates; it's a record-keeping tool, not a source of medical advice.

Why tirzepatide and pregnancy timing runs shorter

It comes down to how long each drug lingers. Semaglutide has an elimination half-life of about 1 week, and the March 2026 Wegovy label says it stays in circulation for about 5 to 7 weeks after the last 2.4 mg or 7.2 mg dose. Tirzepatide's half-life is about 5 days, or 5 to 6 days in people with overweight or obesity, according to the February 2026 Zepbound label.

Pharmacologists usually treat a drug as mostly cleared after about five half-lives. For tirzepatide that's roughly 25 to 30 days. That's close to UK guidance on Mounjaro and pregnancy, which reportedly asks people to stop at least one month before trying to conceive. The US Zepbound label doesn't name a number, so the timing is something to settle with your prescriber.

Five half-lives is the usual yardstick for clearance. At about 5 days each, tirzepatide is largely gone in a month. Semaglutide, at about a week each, takes closer to five to seven weeks.

Wegovy and pregnancy, and the two month rule

What the label actually says

The Wegovy label is blunt: discontinue at least 2 months before a planned pregnancy to account for semaglutide's long half-life. If someone using it for weight reduction becomes pregnant, the label says to stop. The one carve-out is MASH with advanced liver fibrosis, where use during pregnancy continues only if the benefit justifies the risk to the fetus.

• Stop at least 2 months before a planned pregnancy
• Semaglutide half-life is about 1 week
• Drug stays in circulation 5 to 7 weeks after the last dose
• Wegovy pregnancy registry phone line is 1-877-390-2760

Why Ozempic and pregnancy follow the same math

Ozempic contains the same semaglutide molecule, so the same half-life applies. Ozempic and pregnancy questions usually come from people with type 2 diabetes, where blood sugar control before conception matters as much as the washout. That's exactly why the plan belongs with a prescriber rather than a forum thread.

Weight loss offers no benefit to a pregnant patient and may cause fetal harm. That exact sentence appears in both the Wegovy and the Zepbound prescribing information.

Zepbound and birth control during each dose increase

Here's the part many people miss. Tirzepatide slows stomach emptying, and that can blunt the pill. In the label's interaction study, a single 5 mg dose cut peak levels of ethinyl estradiol by 59%, norgestimate by 66% and norelgestromin by 55%, while overall exposure fell by 20% to 23%.

So the Zepbound label advises anyone on oral hormonal contraceptives to switch to a non-oral method or add a barrier method for 4 weeks after starting and for 4 weeks after each dose escalation. The effect is largest after the first dose and shrinks over time. Hormonal methods that aren't swallowed, such as patches, rings, implants and hormonal IUDs, shouldn't be affected, according to the label.

Which methods the label covers

• Oral pills: switch or add a barrier method for 4 weeks
• The 4-week window restarts after every dose escalation
• Non-oral hormonal methods should not be affected
• Gastric emptying delay is biggest after the first dose

When Zepbound and pregnancy overlap

If a pregnancy is recognized, the label says to stop Zepbound and notes that appropriate weight gain is recommended for all pregnant patients. Lilly runs a pregnancy exposure registry at 1-800-545-5979, and the label encourages exposed patients and their clinicians to contact it.

What the timing costs you in weeks of treatment

The contraception rule adds up faster than it looks. Zepbound starts at 2.5 mg and climbs in 2.5 mg steps, with at least 4 weeks on each dose, up to 15 mg, as laid out in our tirzepatide dosage chart. Someone titrating straight through has one start plus five escalations.

A full Zepbound titration to 15 mg can mean 24 weeks of backup contraception for pill users, spread across six separate 4-week windows.

On the semaglutide side, a 2 month washout means about 8 weekly doses skipped before trying to conceive. Trials show weight tends to return once treatment stops, which our piece on stopping Ozempic covers in detail. That's worth raising with your clinician when you plan the gap.

Dates are what make these windows manageable. Logging the day of each dose change in Redose, or in a paper notebook, gives you and your prescriber the same timeline, and the Redose dose calculators keep the syringe math straight if you're on vials. If a weekly dose slips, our guide to missed doses explains how the labels handle it.

Ozempic breastfeeding and the milk studies

Breastfeeding data are thin, but they're more reassuring than the pregnancy data. A 2024 study in Nutrients tested milk from 8 women injecting 0.25 mg to 1 mg of semaglutide weekly, sampled at 0, 12 and 24 hours after a dose, and found no measurable drug in any sample.

Tirzepatide has a similar single-dose result on its label. After one 5 mg injection in 11 lactating women, tirzepatide was undetectable in 164 of 171 milk samples, and the total amount found was under 0.02% of the mother's dose. Neither study measured effects on babies or on milk supply over months.

• Semaglutide injection: no measurable drug in milk from 8 women
• Tirzepatide: undetectable in 164 of 171 milk samples
• Wegovy tablets: breastfeeding is not recommended on the label

Why the Wegovy pill is different

The oral Wegovy tablet contains an absorption enhancer called SNAC, which does show up in breast milk. Because infants may clear it slowly, the label says breastfeeding isn't recommended on the tablets. For the injection, the label says there are no data and leaves the call to the patient and clinician.

What the GLP-1 pregnancy data show so far

If you've typed "glp 1 pregnancy" into a search bar, most of what comes back traces to one large study. A 2023 JAMA Internal Medicine cohort covered about 3.5 million pregnancies in Finland, Iceland, Norway, Sweden, the US and Israel. Among 51,826 pregnancies in women with type 2 diabetes, babies exposed to GLP-1 drugs and other second-line medicines around conception had no higher risk of major malformations than those exposed to insulin.

That's encouraging, not conclusive. The comparison was against insulin rather than unexposed pregnancies, and the authors called some estimates imprecise. Diabetes itself raised the malformation rate to 5.58%, against 3.76% in the general population, and both labels still say the human data are insufficient to establish a drug-related risk.

Common questions about GLP-1 pregnancy planning

Can you get pregnant while taking Zepbound?

Yes. The pill interaction makes the 4 weeks after starting or raising the dose the riskiest stretch for anyone relying on oral contraception. Ask your prescriber which non-oral or barrier method fits your situation.

How long before trying to conceive should you stop Wegovy?

The US label says at least 2 months, because semaglutide stays in the body for 5 to 7 weeks after the last dose. Your prescriber may adjust the plan around other conditions such as diabetes, so treat 2 months as the label minimum rather than a personal schedule.

What happens if you find out you're pregnant on a GLP-1?

Both labels say to stop once pregnancy is recognized, apart from Wegovy for MASH, where the benefit may justify continuing. Contact your prescriber or obstetrician and ask about the manufacturer registries: 1-877-390-2760 for Wegovy and 1-800-545-5979 for Zepbound.

Does Mounjaro carry the same birth control warning?

Mounjaro is the same tirzepatide, and its US label carries the same advice to switch from the pill or add a barrier method for 4 weeks after starting and after each dose increase. The UK regulator repeated that warning in June 2025 and urged effective contraception for anyone on these drugs.

Track every dose change with confidence. Download Redose and get exact syringe units from the calculator, gentle reminders, injection site rotation, and a complete private log of your titration dates to share with your prescriber. Get the app here: iOS.